Your browser doesn't support javascript.
loading
Real-world outcomes associated with liposomal irinotecan dose reductions in metastatic pancreatic ductal adenocarcinoma.
Kim, George P; Surinach, Andy; Corvino, Frank A; Cockrum, Paul; Belanger, Bruce; Abushahin, Laith.
Affiliation
  • Kim GP; Division of Hematology & Oncology, George Washington University, Washington DC 20052, USA.
  • Surinach A; Genesis Research, Hoboken, NJ 07030, USA.
  • Corvino FA; Genesis Research, Hoboken, NJ 07030, USA.
  • Cockrum P; Ipsen, Cambridge, MA 02142, USA.
  • Belanger B; Ipsen, Cambridge, MA 02142, USA.
  • Abushahin L; Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.
Future Oncol ; 17(6): 675-688, 2021 Feb.
Article in En | MEDLINE | ID: mdl-33070660
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pancreatic Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Carcinoma, Pancreatic Ductal / Irinotecan Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Future Oncol Year: 2021 Type: Article Affiliation country: United States
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pancreatic Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Carcinoma, Pancreatic Ductal / Irinotecan Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Future Oncol Year: 2021 Type: Article Affiliation country: United States